TEST:

Syantra DX™ Breast Cancer test

"Cancer diagnostics developer Syantra said Wednesday that it has raised C$4.9 million (US$3.6 million) in a Series A-1 financing round...Syantra said it will use the Series A-1 funding to fast-track the clinical validation and commercialization of the breast cancer test."

"The University of Calgary is working with Cornell University to clinically validate a liquid biopsy test for the early detection of breast cancer with the support of approximately $2.4 million in funding from the US Department of Defense."

"Syantra announced...that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat."